Journal of Medicinal Chemistry

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

EQS-News: Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, PMS, Multiple sclerosis, Woman, Disease, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

“With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • “With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, Entire, PMS, Multiple sclerosis, Woman, Disease, Sirtuin 6, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

"With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • "With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Retrieved on: 
Monday, November 27, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Psilocybin, Medicinal chemistry, Absorption, Depression, American Chemical Society, Prodrug, Toxicology, ACS, Addiction, Journal, Therapy, Anxiety, Journal of Medicinal Chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).
  • The modifications made in the generation of the library of compounds offer the potential to reduce the duration of the psychedelic experience generated by psilocybin, while maintaining the long-term mental health benefits of psilocin.
  • “The publication in the Journal of Medicinal Chemistry, notably as the issue’s cover article, is a major step in validating the proficiency of Enveric’s innovation engine by demonstrating the comprehensive processes employed to rapidly generate and screen a large library of novel psilocin compounds,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
  • The company expects to complete all enabling preclinical studies by the end of 2023.

Think Bioscience Appoints Wendy Young, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023
Molecule, American Cancer Society, Genomics, Therapy, Scio Diamond Technology Corporation, GV (company), Wake Forest University, Medicinal chemistry, Research, Protein, Journal, Journal of Medicinal Chemistry, Senior, Princeton University, Celera Corporation, Memorial Sloan Kettering Cancer Center, Multiple sclerosis, Genentech, BTK, Chemistry, Patient, Coronavirus Scientific Advisory Board, Pharmaceutical industry, List of life sciences

BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young, Ph.D., to its Scientific Advisory Board. Dr. Young is a seasoned pharmaceutical professional with 30+ years of experience in small molecule research and development

Key Points: 
  • Think Bioscience brings on accomplished biotech executive and drug discovery veteran Wendy Young, Ph.D.
    BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young , Ph.D., to its Scientific Advisory Board.
  • "We are excited to leverage her deep expertise to build Think into an industry-leading research and development organization."
  • Dr. Young currently serves as a director and/or scientific advisor to several biotech companies and is an advisor at Google Ventures.
  • "I'm excited by the elegance of the Think Bioscience platform, which can discover new functional binding sites and access novel chemical matter.

Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member

Retrieved on: 
Thursday, September 7, 2023
Mental Health, Health, Neurology, Research, Science, Pharmaceutical, Biotechnology, Molecule, Medicinal chemistry, Memorial Sloan Kettering Cancer Center, Senior, Samuel, Marketing, Ironwood Pharmaceuticals, Genomics, Journal of Medicinal Chemistry, Coronavirus Scientific Advisory Board, Multimedia, GV (company), Multiple sclerosis, Scio Diamond Technology Corporation, Genentech, Princeton University, BTK, Constipation, Genzyme, Chemistry, DSM-IV codes, Celera Corporation, Journal, Patient, Laboratory, Seizure, RAPS, American Cancer Society, Therapy, Pharmaceutical industry, Rapport, Boston College

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.
  • Ms. Gault comes to Rapport from Cyclerion Therapeutics, where she was Chief Operating Officer overseeing corporate and business development, portfolio strategy, new product planning and corporate strategy functions.
  • Ms. Gault also served at Genzyme Corporation in a variety of sales and marketing roles in the biosurgery division.
  • She currently serves on the boards of directors and scientific advisory boards of several biotech companies and is an advisor at Google Ventures.

EQS-News: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Retrieved on: 
Wednesday, May 17, 2023
Neuroprotection, Sclerosis, Medicinal chemistry, GFAP, Glial fibrillary acidic protein, Ludwig Maximilian University of Munich, AFL, Biotechnology, Medication, DHODH, Journal of Medicinal Chemistry, Patent, Patient, Calcium, Frankincense, Pharmaceutical industry, Vaccine, Multiple sclerosis, Short course immune induction therapy

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Key Points: 
  • Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
    The issuer is solely responsible for the content of this announcement.
  • Activation of Nurr1 could be responsible for the drug’s postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in multiple sclerosis patients.
  • Specifically, preclinical data shows potent Nurr1 activation by vidofludimus calcium at low concentrations in several test systems.
  • In preclinical testing, we have discovered strong Nurr1 agonism by vidofludimus calcium,” stated Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic.

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

Retrieved on: 
Monday, December 19, 2022
Cancer, Journal, Research, Phosphorylation, RAS, Attention deficit hyperactivity disorder predominantly inattentive, Patient, Journal of Medicinal Chemistry, Treatment, Medicinal chemistry, Large-cell lung carcinoma, Manuscript, NSCLC, Neoplasm, Pharmaceutical industry

REDWOOD CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced publication of a manuscript in the Journal of Medicinal Chemistry that details the discovery efforts leading to RMC-5552, the company’s first-in-class, bi-steric mTORC1-selective inhibitor. The manuscript describes the unprecedented compound profile that includes 40-fold selectivity for mTORC1 over mTORC2 and greater than 53-fold selectivity over other lipid kinases. The paper also shows that selective mTORC1 inhibition using the company’s related preclinical tool compound (RMC-6272) in combination with a covalent KRASG12C inhibitor induced tumor regressions in a preclinical model of KRASG12C mutant non-small cell lung cancer (NSCLC) that exhibits resistance to KRASG12C inhibitor monotherapy.

Key Points: 
  • The manuscript describes the unprecedented compound profile that includes 40-fold selectivity for mTORC1 over mTORC2 and greater than 53-fold selectivity over other lipid kinases.
  • RMC-5552 is designed to suppress phosphorylation and inactivation of 4EBP1, a key translational regulator of oncogene expression, in cancers with hyperactive mTORC1 signaling.
  • Revolution Medicines is currently evaluating RMC-5552 as monotherapy in a Phase 1/1b clinical trial in patients with refractory solid tumors ( NCT04774952 ), and initial antitumor activity has been reported.
  • “The Journal of Medicinal Chemistry manuscript details the sophisticated structure-based chemical design and synthesis employed by our drug discovery team that produced RMC-5552,” said Steve Kelsey, M.D., president, research and development at Revolution Medicines.

Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Crave, Doctor of Pharmacy, Sleep, Maintenance, Therapy, Interstitial, Physician, M.A, AAAP, Addiction psychiatry, Conditional sentence, Polysomnography, AUD, Central nervous system, Eileen Brooke, American Academy, PSG, Patient, Prevalence, Somnolence, Alcoholism, Architecture, FDA, Peripheral nervous system, Pain, CI, Wakefulness, Journal of Medicinal Chemistry, NOP, PACS, LSM, Safety, Gene–environment correlation, Preclinical development, Overactive bladder, Anxiety, American Academy of Addiction Psychiatry, Kolla, Pharmaceutical industry, Mare Imbrium, Insomnia

The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).

Key Points: 
  • The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
  • Sunobinop is an internally discovered oral compound being evaluated as a potential treatment for multiple disorders including insomnia during recovery from AUD.
  • The Phase 2 randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical study enrolled 114 people experiencing insomnia during recovery from AUD.
  • Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, Partnership, Research, Risk, Genome, Therapy, PKMYT1, Company, Program, Security (finance), CMC, ATR, ATM, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Compliance, Neoplasm, Patient, FOLFIRI, AMF, COVID-19, Private Securities Litigation Reform Act, Carboplatin, SOX, Neutrophil, DNA repair, D&O, Review, HSR, DNA, Medicinal chemistry, Safety, CRISPR, Net, EPS, CCNE1, Journal of Medicinal Chemistry, Insurance, Cell death, Pharmaceutical industry, Medical imaging, Fine chemical, IND, G&A, Reparenting

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.
  • In connection with this agreement, Repare received a $125 million upfront payment in July 2022 and may expect to receive up to $55 million in potential near-term payments.
  • Third Quarter 2022 Review and Operational Updates:
    Evaluating RP-6306, a first-in-class, oral PKMYT1 inhibitor as a monotherapy and in combinations in multiple Phase 1 studies.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.